These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 36977709)

  • 21. Quasi-partial order continual reassessment method: Applying toxicity scores to cancer dose-finding drug combination trials.
    O'Connell NS; Wages NA; Garrett-Mayer E
    Contemp Clin Trials; 2023 Feb; 125():107050. PubMed ID: 36529437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomes.
    Resche-Rigon M; Zohar S; Chevret S
    Clin Trials; 2008; 5(6):595-606. PubMed ID: 19029208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An evaluation of phase I clinical trial designs in the continuous dose-response setting.
    Storer BE
    Stat Med; 2001 Aug; 20(16):2399-408. PubMed ID: 11512130
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose-finding design for multi-drug combinations.
    Wages NA; Conaway MR; O'Quigley J
    Clin Trials; 2011 Aug; 8(4):380-9. PubMed ID: 21652689
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multi-stage dose expansion cohort (MSDEC) design with Bayesian stopping rule.
    Wang S; Tan M
    J Biopharm Stat; 2022 Jul; 32(4):600-612. PubMed ID: 35699319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extending the Continual Reassessment Method to accommodate step-up dosing in Phase I trials.
    Braun TM; Mercier F
    Stat Med; 2022 Sep; 41(20):3975-3990. PubMed ID: 35662077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A hybrid Bayesian adaptive design for dose response trials.
    Chang M; Chow SC
    J Biopharm Stat; 2005; 15(4):677-91. PubMed ID: 16022172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systematic comparison of the statistical operating characteristics of various Phase I oncology designs.
    Ananthakrishnan R; Green S; Chang M; Doros G; Massaro J; LaValley M
    Contemp Clin Trials Commun; 2017 Mar; 5():34-48. PubMed ID: 29740620
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Some practical improvements in the continual reassessment method for phase I studies.
    Goodman SN; Zahurak ML; Piantadosi S
    Stat Med; 1995 Jun; 14(11):1149-61. PubMed ID: 7667557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
    Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
    Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A web tool for designing and conducting phase I trials using the continual reassessment method.
    Wages NA; Petroni GR
    BMC Cancer; 2018 Feb; 18(1):133. PubMed ID: 29402249
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bayesian interval-based oncology dose-finding design with repeated quasi-continuous toxicity model.
    Zhao D; Zhu J; Wang L
    Contemp Clin Trials; 2021 Mar; 102():106265. PubMed ID: 33418097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method.
    Bayar MA; Ivanova A; Le Teuff G
    Comput Methods Programs Biomed; 2019 Jul; 176():211-223. PubMed ID: 31200907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
    Normolle D; Lawrence T
    J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modeling adverse event counts in phase I clinical trials of a cytotoxic agent.
    Muenz DG; Braun TM; Taylor JM
    Clin Trials; 2018 Aug; 15(4):386-397. PubMed ID: 29779418
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Posterior maximization and averaging for Bayesian working model choice in the continual reassessment method.
    Daimon T; Zohar S; O'Quigley J
    Stat Med; 2011 Jun; 30(13):1563-73. PubMed ID: 21351288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An evaluation of phase I cancer clinical trial designs.
    Ahn C
    Stat Med; 1998 Jul; 17(14):1537-49. PubMed ID: 9699228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Performance of phase-I dose finding designs with and without a run-in intra-patient dose escalation stage.
    Labrenz J; Edelmann D; Heitmann JS; Salih HR; Kopp-Schneider A; Schlenk RF
    Pharm Stat; 2023 Mar; 22(2):236-247. PubMed ID: 36285348
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A default method to specify skeletons for Bayesian model averaging continual reassessment method for phase I clinical trials.
    Pan H; Yuan Y
    Stat Med; 2017 Jan; 36(2):266-279. PubMed ID: 26991076
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Robust EM Continual Reassessment Method in Oncology Dose Finding.
    Yuan Y; Yin G
    J Am Stat Assoc; 2011 Sep; 106(495):818-831. PubMed ID: 22375092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.